Company intelligence / Profile preview

Forward

Ownership: Private
Development stage: Phase 2

Overview

Forward Therapeutics is developing next-generation oral small molecule therapies targeting validated immunology pathways for chronic inflammatory diseases. The lead program targets TNF-alpha modulation and is currently at the preclinical stage. The company recently raised $50 million in Series A financing to advance its pipeline toward clinical trials. No clinical results have been published yet.

Therapeutic areas: Immunology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

4 assets

WVE-006

Clinical

Indications: Alpha-1 antitrypsin deficiency

3 more assets in the full pipeline.

Request access →

Partnerships

Curie.Bio was instrumental as an incubator/backer during early funding rounds.

Beyond the preview

Go deeper on Forward.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Forward.

Explore the full profile